Incidence trends of adult malignant brain tumors in Finland, 1990–2006 by Natukka, Tuomas
  
Tuomas Natukka 
INCIDENCE TRENDS OF ADULT MALIGNANT 
BRAIN TUMORS IN FINLAND, 1990–2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lääketieteen ja terveysteknologian tiedekunta 
Syventävien opintojen kirjallinen työ 
Syyskuu 2019  
  
TIIVISTELMÄ 
Tuomas Natukka: Incidence trends of adult malignant brain tumors in Finland, 1990–2006 
Syventävien opintojen kirjallinen työ 
Tampereen yliopisto 
Lääketieteen lisensiaatin tutkinto-ohjelma 
Syyskuu 2019 
 
Useissa tutkimuksissa on havaittu pahanlaatuisten aivokasvaimien ilmaantuvuuden lisääntyneen viime 
vuosikymmeninä aina 1990-luvun alkuun saakka, jolloin kasvava trendi on tasaantunut. Kuitenkin jotkut 
tutkimukset ovat raportoineet ilmaantuvuuden kasvaneen myös 2000-luvulla. Tutkimuksemme tavoitteena on 
tutkia malignien glioomien ilmaantuvuustrendejä Suomessa vuosina 1990–2006 ja selvittää, onko trendeissä 
tapahtunut muutoksia. 
 
Keräsimme Suomen Syöpärekisteristä tiedot 4 730:stä potilaasta, joilla oli todettu pahanlaatuinen gliooma. 
Näistä laskimme glioomien ikävakioituja ilmaantuvuuslukuja. Lisäksi tutkimme ilmaantuvuustrendejä sekä 
histologisen tyypin että kasvaimen sijainnin osalta laskemalla keskimääräisiä vuosittaisia muutoksia 
ilmaantuvuusluvuissa. 
 
Miehillä pahanlaatuisten glioomien ikävakioitu ilmaantuvuus oli 9,3/100 000 ja naisilla 6,3/100 000. Kaikkien 
malignien aivokasvaimien yhteenlaskettu ilmaantuvuus pysyi tasaisena läpi tarkastelujakson, eikä trendissä 
havaittu muutosta. Ikäryhmittäisessä analyysissä havaitsimme ilmaantuvuuden kasvavan ainoastaan yli 80-
vuotiaiden ikäryhmässä. Histologisten alatyyppien osalta ilmaantuvuus kasvoi anaplastisissa 
oligodendroglioomissa, oligoastrosytoomissa ja määrittelemättömissä maligneissa glioomissa. Laskevia 
ilmaantuvuuksia havaitsimme astrosytoomissa ja määrittelemättömissä aivokasvaimissa. Kasvaimen sijainnin 
perusteella tehdyssä analyysissä ilmaantuvuus kasvoi frontaalilohkon, aivorungon ja määrittelemättömän 
sijainnin kasvaimissa. Sitä vastoin ilmaantuvuus laski parietaalilohkojen, isoaivojen ja aivokammioiden 
kasvaimissa. 
 
Kaiken kaikkiaan emme havainneet maligneilla glioomilla nousevaa ilmaantuvuustrendiä. Vanhimmassa 
ikäryhmässä ilmaantuvuustrendi oli nouseva, mikä on kuitenkin havaittu aiemmin monissa muissakin 
väestöissä. 
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1 ABSTRACT 
 
 
1.1 Background 
 
Several studies have reported increased incidence trends of malignant gliomas in the late 1900’s 
with a plateau in the 2000’s, but also some recent increases have been reported. The purpose of our 
study was to analyze incidence trends of malignant gliomas in Finland between 1990 and 2006 by 
morphology and site. 
 
1.2 Methods 
 
Data on 4,730 malignant glioma patients were obtained from the nationwide, population-based 
Finnish Cancer Registry. Age-standardized incidence rates and average annual percent changes in 
the incidence rates were calculated by histological subtype and tumor location. 
 
1.3 Results 
 
The incidence rate of gliomas was 9.3 per 100,000 for men and 6.5 for women. The incidence of all 
gliomas combined was stable (annual percent change +0.1%; 95% CI: −0.5, +0.7), with no 
departure from linearity. In an analysis by age group, increasing incidence was found only for ages 
80 years and older. Incidence rates were increasing in anaplastic oligodendroglioma, 
oligoastrocytoma and unspecified malignant glioma, with a minor increase also for glioblastoma. 
Correspondingly, decreasing rates were observed for astrocytoma and unspecified brain tumors. As 
for tumor location, incidence was increasing for frontal lobe and brainstem tumors, as well as those 
with an unspecified location, but decreasing for the parietal lobes, cerebrum and ventricles. 
 
1.4 Conclusions 
 
No increasing incidence trend was observed for all malignant gliomas combined. An increasing 
incidence trend of malignant gliomas was found in the oldest age group.  
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2 INTRODUCTION 
 
 
Gliomas comprise a heterogenous group of brain tumors originating from glial cells. They are the 
most common malignant central nervous system (CNS) tumors (80%) (1). However, age-
standardized incidence rate (adjusted to world standard population) of malignant CNS tumors in 
Europe is 5.5/100,000, making it only the fifteenth most common cancer type (2). Despite their 
rarity, malignant gliomas contribute disproportionately to cancer mortality, because of their poor 
prognosis (3). Although the prognosis of malignant glioma has improved during the recent decades, 
mortality is still very high (4, 5).  
 
Several studies have reported increasing incidence of gliomas, especially among the elderly, until 
the early 1990’s, when the increasing trend has leveled off (6–11). The increasing incidence rates 
can be partly explained by the introduction of CT and MRI during the 1970’s and 1980’s, resulting 
in detection of cases that would have remained undiagnosed earlier (12). Even though several recent 
studies have shown stable incidence (6–8, 11, 13–18), the findings have not been entirely consistent 
(4, 19–21).  
 
Our aim is to analyze incidence trends of malignant gliomas by histological type and anatomic 
location using data from a well-established, high-quality cancer registry with nationwide coverage.  
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3 MATERIALS AND METHODS 
 
 
3.1 Data sources 
 
The data for the study were obtained from the Finnish Cancer Registry (FCR) on all primary 
malignant brain tumors (ICD-O-3 morphology codes 9380–9451) and unspecified malignant brain 
tumors (ICD-O-3 morphology code 8000) diagnosed during 1990–2006. The cancer registry data 
covered date of diagnosis, primary site, histological type, malignancy and any previous cancers. Sex 
and age of the patient were reported, but no personal identifiers (or date of birth) were obtained. 
 
The histological (morphology) classification of brain tumors used at FCR prior to 2008 was very 
crude and did not comply with ICD-O. Therefore, detailed histological type, grading and location of 
the tumor were abstracted from the text fields in the cancer notifications (altogether 9,389 clinical 
notifications and 13,217 laboratory notifications on 5,638 unique cancer patients, including 
subsequently excluded cases). In Finland, unique personal identification codes have been widely 
used since the late 1960’s. They allow unequivocal identification (barring errors) and are used for 
elimination of duplicate records and for deterministic record linkage. Based on the detailed 
diagnostic information in the text fields of the cancer registry notifications, tumor histological type 
and anatomic site were systematically reclassified according to ICD-O-3 (22). Clinical notifications 
were primarily used to define tumor location and laboratory notifications for morphology. Data on 
population size by age, gender and calendar year for calculation of incidence rates were obtained 
from Statistics Finland (23).  
 
3.2 Classification and exclusion criteria 
 
We focused on adult malignant gliomas in the brain (ICD-O-3 topography code C71). Therefore, 
tumors located outside the brain and all metastatic tumors were excluded. Patients younger than 20 
years were also excluded, because brain tumors in children and adolescents are biologically 
different from adults (1, 24), and we wanted to focus on a homogenous tumor entity. Benign 
(grade I) brain tumors according to the 2007 WHO classification of CNS tumors were also 
excluded (25). If the initial histological type was subsequently reclassified as other than malignant 
glioma, the tumor was excluded. Table 1 shows subtypes of malignant glioma included in our 
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study. Unspecified brain tumors (ICD-O-3 morphology code 8000 with topography code C71) were 
also included as a separate category. 
 
Primary site of origin was defined based on ICD-O-3 topography classification. Cases with two 
locations (for example frontotemporal) were classified as reported for the most common 
combinations (subsites that comprised over one percent of all tumors). If three or more locations 
were reported, the location was classified as overlapping. Uncommon site combinations (subsites 
with two locations comprising less than one percent of all tumors) were combined as ‘other 
specified locations’. 
 
Table 1. Brain tumor subtypes classified as malignant glioma in our study. 
 
Glioma subtype Morphology code 
Astrocytic tumors  
 Astrocytoma 9400, 9411, 9420 
 Anaplastic astrocytoma 9401 
 Glioblastoma 9440–9442 
Oligodendroglial tumors  
 Oligodendroglioma 9450 
 Anaplastic oligodendroglioma 9451 
Oligoastrocytic tumors  
 Oligoastrocytoma grade II and III 9382 
Ependymal tumors  
 Ependymoma 9391, 9393 
 Anaplastic ependymoma 9392 
Other tumors  
 Unspecified malignant glioma 9380 
 Other specified tumors of the brain 9381, 9390, 9424, 9430, 9470, 9471, 9473, 9505 
 Unspecified tumors of the brain 
 
8000 
 
 
3.3 Statistical analyses  
 
We calculated age-standardized incidence rates (ASR) with 95% confidence intervals (CI) for all 
tumors combined, by gender, calendar year, histological type and anatomic location using the 2013 
European standard population (26). Age-specific incidence rates were calculated for 10-year age 
groups. 
 
Age- and gender-adjusted incidence trends for each histological subtype and location were analyzed 
using Poisson regression, with number of cases as the outcome and population size as the offset 
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term to estimate the average annual percent change (APC) in incidence rate. Mutually adjusted 
gender- and age group-specific incidence trends were also analyzed. For incidence trend analyses, 
we used the classification principles presented above, with the exception that we assigned cases 
with two locations by dividing a half case to both locations. Thereby, only ICD-O-3 codes C71.0–
C71.9 were used for incidence trend analyses. 
 
We investigated whether the incidence trend deviated from linearity by adding calendar year of 
diagnosis as a categorical variable to the Poisson regression model containing a linear term for year, 
with a significant categorical term indicating a departure from linearity. In addition, we further 
investigated the possible deviation from linearity by adding squared year term as a continuous 
variable to the Poisson regression model. We also analyzed whether the incidence trends differed 
significantly between subgroups defined by gender, age group, histological type or anatomic 
location by adding an interaction term (the product of year and gender, and in a separate analysis of 
year and age group, year and histological type or year and anatomic location) to the Poisson 
regression model, and used the likelihood ratio test to compare the goodness of fit of the two nested 
models. In a sensitivity analysis, we evaluated whether distributing unspecified malignant gliomas 
and unspecified tumors of the brain to the specific histological subtypes by the percentage of each 
subtype (assuming the information was missing at random) affected the incidence trends. Statistical 
analyses were performed using Stata (version 15.1) and Microsoft Excel (version 16.0).  
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4 RESULTS 
 
 
Between 1990 and 2006, 4,730 malignant glioma cases in adults were reported to the FCR. The 
ASR of all gliomas combined was 7.7/100,000 (95% CI: 7.5–7.9/100,000) (Table 2). Gliomas were 
more common in men (2,542 cases, 53.7%), with an ASR of 9.3/100,000 (95% CI: 8.9–
9.6/100,000). In women, the ASR was 6.5/100,000 (95% CI: 6.3–6.8/100,000). Most malignant 
gliomas were diagnosed in the age group 60–69 years (1,026 cases, 21.7%), but the highest age-
specific incidence rate was in the ages 70–79 years (15.2/100,000; 95% CI: 14.2–16.2/100,000). 
Incidence increased with age at an average rate of 37.6% (95% CI: +35.4, +39.9) increment per 
each decade of age. Astrocytic tumors comprised 70.6% of all gliomas, and glioblastoma was the 
most common histological subtype (2,284 cases, 48.3%), ASR being 3.8/100,000 (95% CI: 3.7–
4.0/100,000). Unspecified tumors of the brain comprised 12.5% of all tumors (590 cases).  
 
Most malignant gliomas were located in the cerebral lobes (73.4%) (Table 3). Frontal lobe was the 
most common location with 1,108 cases (23.4%), ASR being 1.7/100,000 (95% CI: 1.6–
1.8/100,000). Temporal lobe was almost as common with 969 cases (20.5%), and an ASR of 
1.6/100,000 (95% CI: 1.5–1.7/100,000). Tumors with an unspecified location comprised 11.2% of 
all gliomas. 
 
Table 2. Incidence of adult malignant brain tumors by gender, age, year and histological type in 
Finland 1990–2006. 
 
 Frequency  Age-standardized incidence 
rate (/100,000) 
 n %  Rate 95% CI 
Total 4,730 100.0  7.7 7.5–7.9 
Gender      
 Male 2,542 53.7  9.3 8.9–9.6 
 Female 2,188 46.3  6.5 6.3–6.8 
Agea      
 20–29 268 5.7  2.4 2.1–2.7 
 30–39 513 10.8  4.1 3.8–4.5 
 40–49 705 14.9  5.2 4.9–5.6 
 50–59 932 19.7  8.1 7.6–8.7 
 60–69 1,026 21.7  12.2 11.5–13.0 
 70–79 909 19.2  15.2 14.2–16.2 
 80+ 
 
377 8.0  12.6 11.3–13.9 
aUnadjusted incidence rates      
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 Frequency  Age-standardized incidence 
rate (/100,000) 
 n %  Rate 95% CI 
Year      
 1990 249 5.3  7.3 6.4–8.3 
 1991 254 5.4  7.5 6.6–8.4 
 1992 290 6.1  8.4 7.4–9.4 
 1993 249 5.3  7.3 6.4–8.2 
 1994 251 5.3  7.1 6.2–8.0 
 1995 248 5.2  7.0 6.1–7.9 
 1996 293 6.2  8.3 7.4–9.3 
 1997 272 5.8  7.6 6.7–8.5 
 1998 277 5.9  7.7 6.8–8.6 
 1999 275 5.8  7.5 6.6–8.4 
 2000 276 5.8  7.5 6.6–8.4 
 2001 279 5.9  7.5 6.6–8.4 
 2002 318 6.7  8.5 7.6–9.5 
 2003 289 6.1  7.7 6.8–8.6 
 2004 268 5.7  7.1 6.2–8.0 
 2005 337 7.1  8.7 7.8–9.7 
 2006 305 6.4  7.7 6.8–8.6 
Histology      
Astrocytic tumors      
 Astrocytoma 574 12.1  0.8 0.8–0.9 
 Anaplastic astrocytoma 481 10.2  0.7 0.7–0.8 
 Glioblastoma 2,284 48.3  3.8 3.7–4.0 
Oligodendroglial tumors      
 Oligodendroglioma 215 4.5  0.3 0.3–0.3 
 Anaplastic oligodendroglioma 135 2.9  0.2 0.2–0.2 
Oligoastrocytic tumors      
 Oligoastrocytoma grade II and III 238 5.0  0.3 0.3–0.4 
Ependymal tumors      
 Ependymoma 45 1.0  0.1 0.0–0.1 
 Anaplastic ependymoma 16 0.3  0.0 0.0–0.0 
Other tumors      
 Unspecified malignant glioma 111 2.3  0.2 0.2–0.2 
 Other specified tumors of the brain 41 0.9  0.1 0.0–0.1 
 Unspecified tumors of the brain 
 
590 12.5  1.1 1.0–1.2 
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Table 3. Incidence of adult malignant brain tumors by location in Finland 1990–2006. 
 
 Frequency  Age-standardized incidence 
rate (/100,000) 
 n %  Rate 95% CI 
Total 4,730 100.00  7.7 7.5–7.9 
Location      
 Frontal 1,108 23.4  1.7 1.6–1.8 
 Frontotemporal 272 5.8  0.4 0.4–0.5 
 Frontoparietal 
 
146 3.1  0.2 0.2–0.3 
 Temporal 969 20.5  1.6 1.5–1.7 
 Temporoparietal 231 4.9  0.4 0.3–0.4 
 Temporo-occipital 
 
85 1.8  0.1 0.1–0.2 
 Parietal 395 8.4  0.6 0.6–0.7 
 Parieto-occipital 
 
111 2.3  0.2 0.1–0.2 
 Occipital 152 3.2  0.3 0.2–0.3 
 Cerebrum 178 3.8  0.3 0.3–0.3 
 Ventricles 63 1.3  0.1 0.1–0.1 
 Cerebellum 74 1.6  0.1 0.1–0.2 
 Brainstem 97 2.1  0.2 0.1–0.2 
 Overlapping 
 
238 5.0  0.4 0.4–0.5 
 Other specified 82 1.7  0.1 0.1–0.2 
 Unspecified location 
 
529 11.2  0.9 0.8–1.0 
 
Overall, the ASR of gliomas was stable during the study period (Figure 1). The APC in the 
incidence rate of all gliomas was close to zero (APC: +0.1%; 95% CI: −0.5, +0.7) (Table 4). In 
addition, there was no indication of deviation from linearity, i.e. no evidence of change in the 
overall incidence trend during the study period (likelihood ratio test with year as a categorical 
variable p = 0.19; likelihood ratio test with squared year term as a continuous variable p = 0.61). 
Graphical presentation of the annual incidence rates by gender showed no difference in incidence 
trends between genders (Figure 2), which was also confirmed using an interaction term in Poisson 
regression analysis (likelihood ratio test p = 0.33). A difference in incidence trends between the age 
groups was observed, when tested using an interaction term in Poisson regression analysis 
(likelihood ratio test p = 0.001). However, the only significant increase in incidence rates was in the 
oldest age group (80+ years), with an APC of +4.8% (95% CI: +2.6, +7.0) (Table 4). 
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 Figure 1. Incidence trend of malignant gliomas in Finland 1990–2006. 
 
 
 Figure 2. Incidence trends of malignant gliomas by gender in Finland 1990–2006.  
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A difference in incidence trends between histological types was evident (likelihood ratio test 
p < 0.001). The incidence trend of glioblastoma was slightly increasing (APC: +0.8%; 95% CI: 
−0.0, +1.7), while the incidence trend of astrocytoma showed a decrease of −2.8% per year 
(95% CI: −4.4, −1.1) (Table 4). Significant increases in ASRs were also observed for anaplastic 
oligodendroglioma (APC: +6.0%; 95% CI: +2.3, +9.8) and oligoastrocytoma (APC: +6.6%; 
95% CI: +3.8, +9.5). A decreasing ASR was found for unspecified tumors of the brain (APC: 
−4.5%, 95% CI: −6.0, −2.9), whereas incidence of unspecified malignant glioma increased by 
+6.7% per year (95% CI: +2.6, +11.0). In addition, imputing specific histologic types (in similar 
proportion to those with known cell type) to unspecified tumors had no substantial effect on the 
incidence trends (see Supplementary Table 1). 
 
We also found a difference in incidence trends between anatomic locations (likelihood ratio test 
p < 0.001). Incidence trends were increasing for the frontal lobe (APC: +1.7%; 95% CI: +0.6, +2.8), 
brainstem (APC: +5.8%; 95% CI: +1.7, +10.0) and unspecified locations (APC: +2.3%; 95% CI: 
+0.5, +4.1) (Table 4). Trends were decreasing for the parietal lobes (APC: −2.4%; 95% CI: 
−4.0, −0.9), cerebrum (APC: −3.5%; 95% CI: −6.2, −0.7) and ventricles (APC: −6.0%; 95% CI: 
−10.4, −1.4). 
 
Table 4. APC in age- and gender-adjusted incidence trends of gliomas by gender, age, histological 
type and location in Finland 1990–2006. 
 
 
 
  
 Annual percent change 
 APC 95% CI 
Total +0.1 −0.5, +0.7 
Gender   
 Male −0.2 −1.0, +0.6 
 Female +0.5 −0.4, +1.4 
Age   
 20–29 −1.0 −3.3, +1.5 
 30–39  0.0 −1.8, +1.8 
 40–49 −1.1 −2.6, +0.4 
 50–59 +0.3 −1.0, +1.6 
 60–69 −0.5 −1.7, +0.7 
 70–79 +0.2 −1.2, +1.5 
 80+ 
  
+4.8 +2.6, +7.0 
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 Annual percent change 
 APC 95% CI 
Histology   
Astrocytic tumors   
 Astrocytoma −2.8 −4.4, −1.1 
 Anaplastic astrocytoma −0.4 −2.2, +1.4 
 Glioblastomaa +0.8 −0.0, +1.7 
Oligodendroglial tumors   
 Oligodendroglioma −0.2 −2.9, +2.6 
 Anaplastic oligodendroglioma +6.0 +2.3, +9.8 
Oligoastrocytic tumors   
 Oligoastrocytoma grade II and III +6.6 +3.8, +9.5 
Ependymal tumours   
 Ependymoma +4.2 −1.9, +10.8 
 Anaplastic ependymoma −1.2 −10.6, +9.2 
Other tumors   
 Unspecified malignant glioma +6.7 +2.6, +11.0 
 Other specified tumors of the brain +3.0 −3.3, +9.7 
 Unspecified tumors of the brain −4.5 −6.0, −2.9 
Location   
 Frontal +1.7 +0.6, +2.8 
 Temporal −0.6 −1.8, +0.5 
 Parietal −2.4 −4.0, −0.9 
 Occipital −0.1 −2.6, +2.5 
 Cerebrum −3.5 −6.2, −0.7 
 Ventricles −6.0 −10.4, −1.4 
 Cerebellum −3.8 −8.0, +0.5 
 Brainstem +5.8 +1.7, +10.0 
 Overlapping +2.1 −0.6, +4.8 
 Unspecified location +2.3 +0.5, +4.1 
   
Statistically significant APC are in bold (p < 0.05) 
ap = 0.053 
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5 DISCUSSION 
 
 
In analyses of the incidence trends of adult malignant gliomas in Finland during 1990–2006, we 
found no increase for gliomas overall. Also, there was no difference in incidence trends between the 
genders. Incidence rates in the oldest age group (80+ years) increased throughout the study period, 
while younger age groups showed no such increase. Significant increases were observed for 
anaplastic oligodendroglioma, oligoastrocytoma and unspecified malignant glioma. In addition, 
there was some increase in glioblastomas. Astrocytoma and unspecified tumors of the brain, 
however, showed decreasing incidence trends. Incidence rates for tumors in the frontal lobe, 
brainstem and unspecified location increased throughout the study period. In contrast, tumor 
incidence decreased in the parietal lobes, cerebrum and ventricles. 
 
Our results are consistent with most recent studies (6–8, 11, 13–18). Some studies have reported 
increasing trends in young adults in their 20s (6, 18), but increasing trends have been more 
commonly found in the oldest age groups similar to our results (6, 8, 10, 11, 13, 19–21). We also 
found a slightly increasing incidence trend for the most common histological subtype, glioblastoma, 
which is consistent with several other studies (1, 4, 6–8, 10, 16, 17). A study from United States 
showed an increasing incidence trend for gliomas in the frontal lobe and decreasing trends for the 
cerebrum, ventricles and overlapping subtypes (16). Our findings were comparable otherwise, but 
we also found a decreasing trend for tumors in the parietal lobes and an increasing trend for 
brainstem tumors. 
 
Overall age-standardized incidence rate of all gliomas in our study was 7.7/100,000, which is 
relatively high compared to other studies. A Finnish study reported incidence rate of 4.7/100,000 
for all gliomas, but it was based on only 331 cases, and analyses were mainly focused on anatomic 
locations of brain tumors (27). Incidence rates comparable to ours were reported from Northwestern 
England (7.2/100,000) (15). However, several studies have reported lower incidence rates, which 
may be partly attributable to inclusion of children or non-Caucasian ethnic groups, or incomplete 
case ascertainment (7, 14). A number of studies have also reported similar or higher incidence rates, 
but they have covered either all CNS tumors or benign brain tumors, and are therefore not 
comparable (4, 6, 13, 20).  
 
One possible explanation for the increasing incidence in the oldest age group is improvement in 
diagnostics. Availability of MRI and CT scans has increased the use of these diagnostic methods. 
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Besides increasing the overall incidence, more frequent use of MRI imaging may have affected 
particularly the diagnosis of brain stem tumors, which are better visualized with MRI than with CT. 
More active treatment of brain tumors in elderly patients has probably improved the detection and 
diagnostic accuracy of cases in age groups older than 60–70 years, as it has likely increased both 
biopsies and resections, and hence specific diagnoses. 
 
Unspecified brain tumors decreased during the study period and therefore some of the specific 
histological subtypes must have increased simply owing to more accurate diagnostics including 
modern immunohistochemistry, i.e. cases earlier assigned as unspecified were classified more 
accurately in more recent years. In contrast, tumors with unspecified location increased, which 
slightly decreased incidence rates in some specific locations. 
 
Very few countries have a comprehensive, well-established nationwide population-based cancer 
registry with multiple sources of information and documented completeness of coverage. In 
Finland, cancer incidence data have been collected by the FCR since 1953, and notification of 
cancer cases to the registry has been mandatory since 1961. Case notifications are received from 
hospitals, health care professionals, pathology laboratories and Statistics Finland’s cause of death 
data. The data received from different sources are then compared and double-checked to verify the 
accuracy of every diagnosis. Furthermore, the unique personal identification number allows 
elimination of duplicate records. Therefore, our data based on the FCR is very comprehensive and 
reliable. In addition, we abstracted information from every report for each case and reclassified 
histological type and anatomic site of presentation according to ICD-O-3 to improve the accuracy 
and comparability of the classification. (28) 
 
Finland has centralized the treatment of malignant brain tumors into five university hospitals, which 
makes diagnoses very standardized and consistent, thus improving also the reliability of the data at 
the FCR. Also, there were no major changes in brain tumor classification during our study period, 
ensuring consistency of data throughout the study period. 
 
Our study had also some limitations. Re-evaluation of the tumor slides by an experienced 
neuropathologist would have further improved the accuracy and reliability of the diagnoses, but this 
is not feasible in a large population-based study. Therefore, we could not retrospectively apply the 
recent 2016 WHO classification of CNS tumors. Our analysis did not cover the most recent years 
but focused on the time period with insufficient detail of tumor classification at the cancer registry. 
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Also, the number of cases in several subgroups was fairly small, limiting the precision of the 
estimates. We did not conduct join-point analyses, as the incidence rates were very flat. 
 
The stable incidence rates of malignant gliomas suggest no major increase in public exposure to 
major risk factors. Although usage of mobile phones increased dramatically during our study 
period, overall incidence rates of malignant gliomas did not increase at all. Furthermore, we 
observed no increasing incidence rates in the temporal lobes, which are the most exposed part of the 
brain from the radiofrequency electromagnetic fields emitted by mobile phones. 
 
The recently updated 2016 WHO classification of tumors of the CNS is the first to use molecular 
and genetic parameters besides histological features to define several CNS tumor entities including 
malignant gliomas. In the present study, the increase in oligodendroglial tumor incidence and the 
decrease of astrocytoma incidence might be due to the introduction of the chromosome 1p/19q-
analysis in the diagnosis of oligodendrogliomas in the early 2000s (29).  
 
Further studies are necessary to evaluate the impact of the new WHO classification system, and to 
determine the most recent incidence rates. Also, if the latency between radiofrequency field 
exposure and tumor development is very long, future studies with more recent data assessing longer 
exposure and latency periods will be needed. 
 
In conclusion, no increase in adult malignant gliomas overall was found for Finland in 1990–2006. 
However, an increase in the oldest age group was observed, comparable to several other 
populations.  
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9 APPENDICES 
 
 
Supplementary Table 1. APC in age- and gender-adjusted incidence trends of gliomasa by 
histological type in Finland 1990–2006. 
 
 
 Annual percent change 
 APC 95% CI 
Histology   
Astrocytic tumors   
 Astrocytoma −1.8 −3.4, −0.3 
 Anaplastic astrocytoma −0.4 −2.0, +1.3 
 Glioblastoma +0.8 +0.1, +1.5 
Oligodendroglial tumors   
 Oligodendroglioma +0.1 −2.6, +2.8 
 Anaplastic oligodendroglioma +5.3 +1.9, +8.9 
Oligoastrocytic tumors   
  Oligoastrocytoma grade II and III +7.2 +4.4, +10.1 
Ependymal tumours   
 Ependymoma +4.6 −1.0, +10.6 
 Anaplastic ependymoma +0.0 −8.1, +8.8 
Other tumors   
 Other specified tumors of the brain +4.4 −0.9, +10.0 
   
Statistically significant APC are in bold (p < 0.05) 
aSpecific histologic types imputed (in similar proportion to those with known cell type) to 
unspecified tumors 
